New Approaches in the Management of Head and Neck Cancer

Dear Colleagues,

Head and neck cancers are a heterogeneous group of malignant tumors, which often lead to dysphagia, dyspnea, and death. In the past, we have learned that head and neck cancers are not only caused by alcohol and tobacco but also by infection with the human papillomavirus. With the approval of PD1-inhibitors five years ago, the therapeutic approach to head and neck cancers has been reorganized in the palliative setting. Moreover, clinical studies for checkpoint inhibitors in the curative setting are on their way. However, the main challenge for the scientific community seems to be the identification of robust biomarkers. While the main focus is currently on checkpoint inhibitors, other fields of tumor immunology profit from this hype and may soon find their way into clinical routine. This includes vaccination trials, exosomes, liquid biopsies, or targeted therapy. In all cases, the timing and the right combination of therapeutic regimens, including surgery, radiation, chemotherapy, and immunotherapy, may be of great importance. In this Special Issue, experts in this field will review current approaches to the management of patients with head and neck cancers.

Prof. Dr. Patrick J. Schuler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.